SCHEMBL25249092

SCHEMBL25249092

CC(C)(C)OC(=O)n1nc(Cl)cc1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
FAAH O00519 1/20 0.41
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
NR1H2 P55055 1/20 0.36
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.35
MAP2K4 P45985 1/20 0.34
ESR2 Q92731 1/20 0.34
ELANE P08246 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
SMARCA2 P51531 1/20 0.33
SMARCA4 P51532 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL174902 0.82 ALDH1A1 (0.43) HSP90AA1HSP90AB1FAAHKMT2AMEN1
SCHEMBL667656 0.81 KDM4E (0.40) HSP90AA1HSP90AB1FAAHKMT2ANR1H2
SCHEMBL23500483 0.81 FAAH (0.38) HSP90AA1HSP90AB1FAAHNR1H2MAP2K4
SCHEMBL1852959 0.79 TSHR (0.50) HSP90AA1HSP90AB1KMT2AMEN1LMNA
SCHEMBL23500384 0.78 FAAH (0.39) HSP90AA1HSP90AB1FAAHNR1H2MAP2K4
SCHEMBL2484133 0.78 NR1H2 (0.35) HSP90AA1HSP90AB1FAAHNR1H2MAP2K4
SCHEMBL4038261 0.77 NR1H2 (0.36) HSP90AA1HSP90AB1FAAHNR1H2SMN1; SMN2
SCHEMBL1001764 0.76 FAAH (0.35) HSP90AA1HSP90AB1FAAHKMT2AMEN1
SCHEMBL173999 0.76 KDM4E (0.41) HSP90AA1HSP90AB1FAAHKMT2AMEN1
SCHEMBL21643573 0.76 MAP2K4 (0.36) HSP90AA1HSP90AB1FAAHKMT2ANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 US disclosed
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 US disclosed
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 US disclosed
CN-116507337-A ATR inhibitors and uses thereof 上海德琪医药科技有限公司 2023-07-28 CN disclosed
EP-4192836-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-06-14 EP disclosed
WO-2022028598-A1 ATR INHIBITORS AND USES THEREOF SHANGHAI ANTENGENE CORPORATION LIMITED (CN) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ATR, CHEK1, CHEK2 HSP90AA1 840/4885HSP90AB1 625/4885FAAH 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.